%Apple (NASDAQ: AAPL) is removing the Blood Oxygen app from its %AppleWatch Series 9 and Ultra 2 devices to ensure that it can continue selling them in the U.S. market.

A U.S. court had ordered that sales of the Series 9 and Ultra 2 Apple Watches be stopped due to a patent dispute with Masimo, a company that claims the Blood Oxygen app infringes on its technology.

Apple has reportedly shipped the modified Watch Series 9 and Ultra 2 units to its U.S. locations, but stores have been told not to sell the devices until getting the green light from head office.

Late last year, courts found that Apple had violated Masimo’s patents concerning blood oxygen functions on the Apple Watch.

The ruling led Apple to pause sales of the Watch Series 9 and Ultra 2 in the U.S. through its website and at its retail stores during the holiday shopping season.

The current situation does not impact people who already have an Apple Watch with the Blood Oxygen app.

Apple has offered the Blood Oxygen app on its smartwatches since it released the Apple Watch Series 6 in 2020.

While Apple was said to be working on a software update related to the Blood Oxygen function, it was found that removing the app entirely from future devices was the quickest solution.

In a written statement, Masimo said that “Apple's claim that its redesigned watch does not contain pulse oximetry is a positive step toward accountability…”

Masimo claimed in court that Apple hired its former employees and used its pulse oximetry technology in its Apple Watches.

The stock of Apple has gained 37% in the last 12 months to trade at $185.92 U.S. per share.